More GH release does not necessarily mean better sleep. That assumption is especially important to check when a peptide is advertised as helping both recovery and deep sleep through the same mechanism.
A sleep-EEG experiment in seven healthy volunteers found reductions in selected slow-wave-sleep measures after hexarelin under the tested conditions, alongside increases in several hormone measurements. The result challenges a simple “more GH equals better sleep” story.
The small experiment does not establish that every person would experience poorer sleep with every exposure pattern. It also does not identify a useful alternative schedule. Its value is that sleep was measured directly rather than inferred from hormone release.
Subjective sleep and measured sleep are different evidence
Feeling sleepy, remembering fewer awakenings and showing a change in a particular sleep stage are related questions, not identical answers. A testimonial can describe one while implying another.
When reading a sleep claim, ask whether the study measured sleep at all, which method it used, and whether the outcome corresponds to the advertised benefit. “Recovery” is too broad a word unless the actual outcome is explained.
The experiment also compared a defined intervention with placebo. A person combining several products cannot isolate hexarelin's contribution merely by noticing a better or worse night.
Persistent sleep difficulties deserve an assessment that considers the whole problem rather than a search for a stronger secretagogue. If a new symptom appears during use of a product, report the product and timing accurately to a qualified clinician instead of trying to repair the experience with an additional peptide.
This article is not a recommendation to use hexarelin for sleep. It is a specific correction to an unsupported mechanism-to-benefit leap. The measured human finding is small and limited, but it is enough to show why sleep claims must be checked directly rather than borrowed from GH physiology.